CD169+ classical monocyte as an important participant in Graves’ ophthalmopathy through CXCL12-CXCR4 axis

• Published in: iScience Vol. 27; no. 3; p. 109213
• Main Authors: Wang, Dongliang, Ling, Jie, Tan, RongQiang, Wang, Huishi, Qu, Yixin, Li, Xingyi, Lin, Jinshan, Zhang, Qikai, Hu, Qiuling, Liu, Zhong, Lu, Zhaojing, Lin, Yuheng, Sun, Li, Wang, Dingqiao, Zhou, Ming, Shi, Zhuoxing, Gao, Wuyou, Ye, Huijing, Lin, Xianchai
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.03.2024; Elsevier
• Subjects: Immunology; Omics; Immunology; Omics
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2024.109213

Patients with Graves’ disease (GD) can develop Graves’ ophthalmopathy (GO), but the underlying pathological mechanisms driving this development remain unclear. In our study, which included patients with GD and GO, we utilized single-cell RNA sequencing (scRNA-seq) and multiplatform analyses to investigate CD169+ classical monocytes, which secrete proinflammatory cytokines and are expanded through activated interferon signaling. We found that CD169+ clas_mono was clinically significant in predicting GO progression and prognosis, and differentiated into CD169+ macrophages that promote inflammation, adipogenesis, and fibrosis. Our murine model of early-stage GO showed that CD169+ classical monocytes accumulated in orbital tissue via the Cxcl12-Cxcr4 axis. Further studies are needed to investigate whether targeting circulating monocytes and the Cxcl12-Cxcr4 axis could alleviate GO progression. [Display omitted] •scRNA-seq of PBMCs identifies CD169+ clas_mono associated with GO progression•CD169+ clas_mono expansion is related to activated IFNγ signaling pathway in GOs•Circulating monocytes regulate GO development via Cxcl12-Cxcr4 axis Immunology; Omics